Neurogene (NGNE) Enterprise Value (2013 - 2026)
Neurogene (NGNE) posted Enterprise Value of -$243.2 million for Q1 2026, up 9.6% on a QoQ basis from -$269.0 million in Q4 2025, and up 16.89% year-over-year from -$208.0 million in Q1 2025.
Neurogene (NGNE) Enterprise Value (2013 - 2026) Analysis & Trends
Neurogene's Enterprise Value history runs 14 years deep, the most recent figure standing at -$243.2 million for Q1 2026.
- Quarterly Enterprise Value rose 16.89% year-over-year to -$243.2 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$243.2 million (up 16.89% YoY) and the FY2025 annual result came in at -$269.0 million, up 13.89% from the prior year.
- Enterprise Value was -$243.2 million for Q1 2026 at Neurogene, up from -$269.0 million in the prior quarter.
- Across five years, Enterprise Value topped out at -$78.5 million in Q3 2023 and bottomed at -$312.4 million in Q4 2024.
- A 5-year average of -$176.1 million and a median of -$153.9 million in 2024 frame the typical range for Enterprise Value.
- Annual changes were most pronounced in 2022 — Enterprise Value jumped 42.43% — and 2023, when it tumbled 140.37%.
- Neurogene's Enterprise Value stood at -$82.0 million in 2022, then tumbled by 140.37% to -$197.2 million in 2023, then tumbled by 58.45% to -$312.4 million in 2024, then climbed by 13.89% to -$269.0 million in 2025, then rose by 9.6% to -$243.2 million in 2026.
- Business Quant data shows NGNE's Enterprise Value at -$243.2 million in Q1 2026, -$269.0 million in Q4 2025, and -$265.4 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Enterprise Value (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,072.09 Bn | 67,072.09 Bn | - | -283.54 Mn |
| 2 | Nanobiotix | 1,894.61 Bn | 1,894.55 Bn | - | -61.40 Mn |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | -2.83 Mn |
| 4 | BeOne Medicines | 471.64 Bn | 466.85 Bn | 1.35 Bn | -4.79 Bn |
| 5 | Vertex Pharmaceuticals | 121.72 Bn | 114.47 Bn | 2.59 Bn | -7.25 Bn |
| 6 | Regeneron Pharmaceuticals | 68.28 Bn | 59.52 Bn | 3.31 Bn | -8.75 Bn |
| 7 | Belite Bio | 61.40 Bn | 61.40 Bn | - | - |
| 8 | Argenx Se | 56.94 Bn | 56.94 Bn | 1.18 Bn | - |
| 9 | Revolution Medicines | 37.37 Bn | 37.37 Bn | - | -1.91 Bn |
| 10 | Neurogene | 776.69 Mn | 776.69 Mn | - | -243.18 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -243.18 Mn |
| Dec 31, 2025 | -269.01 Mn |
| Sep 30, 2025 | -265.41 Mn |
| Jun 30, 2025 | -274.52 Mn |
| Mar 31, 2025 | -292.60 Mn |
| Dec 31, 2024 | -312.41 Mn |
| Sep 30, 2024 | -138.99 Mn |
| Jun 30, 2024 | -153.91 Mn |
| Mar 31, 2024 | -169.53 Mn |
| Dec 31, 2023 | -197.16 Mn |
| Sep 30, 2023 | -78.51 Mn |
| Jun 30, 2023 | -82.06 Mn |
| Mar 31, 2023 | -83.44 Mn |
| Dec 31, 2022 | -82.02 Mn |
| Sep 30, 2022 | -106.88 Mn |
| Jun 30, 2022 | -116.46 Mn |
| Mar 31, 2022 | -128.06 Mn |
| Dec 31, 2021 | -142.47 Mn |
| Sep 30, 2021 | -154.92 Mn |
| Jun 30, 2021 | -164.24 Mn |